Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-10-24 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi + Imjudo approved in advanced liver cancer
Regulatory Filings Classification · 98% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding paragraph stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a significant regulatory event: the US FDA approval of a drug combination (Imjudo + Imfinzi) for liver cancer, based on Phase III trial results. This is a material corporate announcement disseminated via a regulatory channel. Since it is a specific announcement of a regulatory event (drug approval) and not a full financial report (like 10-K or IR), nor a general proxy/meeting material, the most appropriate classification is the general regulatory announcement category, RNS, as it fits the definition of a 'General regulatory announcement' and is the primary distribution method shown.
2022-10-24 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2022-10-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service) on October 3, 2022. The content explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights (1,549,508,944) as of September 30, 2022. This directly relates to the total capital structure and voting rights, which falls under the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a regulatory filing, DVA is a more specific category than the general RNS fallback.
2022-10-03 English
BOARD COMMITTEE CHANGES
Foreign Filer Report
2022-09-30 English
Board Committee Changes
Remuneration Information Classification · 99% confidence The document is a short announcement (2968 characters) released via RNS (London Stock Exchange news service). The content explicitly details the appointment of a new Chair for the Remuneration Committee and subsequent changes to committee memberships, effective from a future date. This directly relates to the composition and structure of the company's board and governance bodies. While it mentions the Remuneration Committee (which sometimes relates to DEF 14A), the core subject is the change in management/board roles. This fits best under Board/Management Information (MANG). It is not a full report, an earnings release, or a proxy statement.
2022-09-30 English
KOSELUGO APPROVED IN JAPAN FOR NF1
Foreign Filer Report
2022-09-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.